Fig. 4: metCRC PDOs demonstrate similar drug responses. | npj Precision Oncology

Fig. 4: metCRC PDOs demonstrate similar drug responses.

From: A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids

Fig. 4

a Summary of IC50 values when PDOs were grouped according to tumour type. Matched PDOs were highlighted in blue (CRC07), green (CRC08) and red (CRC11). Two-way ANOVA and Šidák’s pairwise comparisons were performed as recommended (n.s. not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Data represented as means ± SD (n = 6 and 4 for primary tumour and metastasis PDOs respectively). b Overview of IC50 when metastases PDOs were stratified based on metastatic site. Two-way ANOVA and Šidák’s pairwise comparisons were performed as recommended, but no statistical difference was identified between liver and ovarian metastases-derived PDOs for all 10 drugs. Data represented as means ± SD (n = 2). (5-FU 5-fluorouracil, OXA oxaliplatin, LEU leucovorin, SN38 SN-38, REG regorafenib, PEM pemrametostat, TP064 TP-064, DEC decitabine, ENT entinostat, VOR vorinostat).

Back to article page